Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of ALG-055009 Formulations in Healthy Volunteers
NCT06959888Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ALG-055009 in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 12 days and 5 more. Started Mar 2025; status: completed.
02
Drugs
ALG-055009
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06959888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959888.